Stage 3 Melanoma: Lymph Node Therapy

Stage 3 melanoma represents a critical juncture in disease progression, where the cancer has spread beyond the primary tumor to nearby lymph nodes. This stage is heterogeneous, encompassing subcategories 3a, 3b, and 3c, each with distinct prognostic and therapeutic implications. Understanding lymph node involvement and the available treatment strategies is essential for patients and clinicians navigating this challenging diagnosis. In this article, we delve into the nuances of this advanced stage, exploring the role of lymphatic spread, common metastasis sites, and modern therapeutic approaches. Whether you are dealing with substage 3a, 3b, or 3c, this guide provides valuable insights into management and outlook.

Melanoma is the most aggressive form of skin cancer, arising from melanocytes. When it reaches regional stage, the prognosis becomes more guarded, but recent advances in immunotherapy and targeted therapy have significantly improved outcomes. The key feature of stage 3 melanoma is the presence of tumor cells in regional lymph nodes, which can be detected through sentinel node biopsy or clinical examination. The extent of nodal involvement, the number of nodes affected, and the presence of ulceration or in-transit metastases define the substage. For instance, substage 3a typically involves microscopic deposits in one or two nodes without ulceration, while 3b and 3c indicate more extensive disease.

What Is Stage 3 Melanoma?

Stage III melanoma is defined by the spread of cancer cells to the lymphatic system. The American Joint Committee on Cancer (AJCC) staging system distinguishes three substages based on tumor thickness (T category), nodal involvement (N category), and absence of distant metastasis (M0). The N category for this stage includes micrometastases (detected by biopsy) or macrometastases (clinically palpable nodes). Additionally, the presence of in-transit or satellite metastases (skin or subcutaneous deposits between the primary site and nodal basin) also qualifies as stage III. The substages—3a, 3b, and 3c—reflect increasing disease burden and worsening prognosis.

Specifically, melanoma 3a refers to a primary tumor with microscopically detected nodal metastases (N1a, N2a) and no ulceration. Melanoma 3b includes cases with clinically detectable nodal metastases (N1b, N2b) or microscopic nodes with ulceration, or in-transit/satellite metastases without nodal involvement. Melanoma 3c involves more than three clinically positive nodes or extensive in-transit/satellite metastases. This classification helps guide treatment decisions and provide prognostic information.

Lymph Node Involvement in Melanoma

The lymphatic system is the primary route for melanoma metastasis. Tumor cells detach from the primary lesion and travel through lymphatic vessels to regional nodes. The first node to receive drainage is the sentinel node, and its status is the most important prognostic factor for early-stage melanoma. In stage 3, the tumor has colonized one or more nodes, leading to potential further spread. The presence of tumor cells in melanoma lymph nodes triggers a systemic immune response and alters the tumor microenvironment.

For patients with stage III melanoma, the number of involved nodes and the presence of extranodal extension are critical. For example, in melanoma 3a, nodes contain microscopic deposits (<2 mm) and are not enlarged. In contrast, melanoma 3b and 3c involve macrometastases that enlarge nodes and may be adherent to surrounding tissues. Lymph node dissection (LND) is often performed to remove all affected nodes, although the role of complete LND has been refined with the advent of effective systemic therapies. Sentinel node biopsy is essential for staging, and if positive, further imaging and treatment planning follow.

• Micrometastases: Tumor deposits ≤2 mm in a lymph node, often detected only by immunohistochemistry.
• Macrometastases: Clinically palpable nodes with visible tumor on imaging or during surgery.
• In-transit metastases: Skin or subcutaneous deposits between the primary site and the nodal basin, indicating lymphatic spread.
• Satellite metastases: Tumor deposits within 2 cm of the primary lesion.

Understanding the pattern of lymphatic spread helps in identifying melanoma metastasis sites. While regional nodes are the first stop, melanoma can also metastasize to distant lymph nodes, skin, subcutaneous tissue, and eventually visceral organs. In stage III, by definition, there is no distant metastasis (M0), but the presence of extensive nodal disease increases the risk of systemic progression. Therefore, effective locoregional control is paramount.

Melanoma Metastasis Sites in Stage 3

While stage III melanoma is confined to the regional lymphatics, the potential for distant spread is ever-present. The most common melanoma metastasis sites include the skin, subcutaneous tissue, and lymph nodes beyond the regional basin. However, in stage III, the focus is on controlling locoregional disease. Common sites for in-transit or satellite deposits are the dermis and subcutis. Additionally, nodal disease can extend to multiple basins if the primary is located in an ambiguous drainage area (e.g., trunk).

For patients with melanoma 3c, the burden of in-transit metastasis can be substantial, requiring multidisciplinary management. Techniques such as isolated limb perfusion or infusion (ILP/ILI) may be employed for extensive extremity involvement. These procedures deliver high-dose chemotherapy directly to the affected limb, sparing systemic toxicity. Understanding the metastatic pattern is crucial for surgical planning and systemic therapy selection.

The biology of melanoma metastasis involves complex interactions between tumor cells and the lymphatic microenvironment. Factors like tumor thickness, ulceration, and mutational profile (e.g., BRAF V600) influence the likelihood of nodal spread. For instance, BRAF-mutant melanomas may have distinct metastatic patterns and response to targeted therapy. Therefore, molecular profiling is recommended for all stage III patients to guide treatment.

Therapy Options for Stage 3 Melanoma

The management of stage III melanoma has evolved dramatically over the past decade. Surgical resection remains the cornerstone, but adjuvant therapy is now standard for high-risk patients. The choice of therapy depends on the substage (3a, 3b, 3c), nodal burden, and patient characteristics. For stage III melanoma with microscopic nodal involvement (3a), observation or clinical trials may be considered, but many experts recommend adjuvant therapy with immune checkpoint inhibitors or targeted agents, especially if the primary is ulcerated or has high-risk features.

For patients with clinically detectable nodes (melanoma 3b and 3c), adjuvant therapy is strongly recommended. The FDA-approved options include:

• Immune Checkpoint Inhibitors: Nivolumab and pembrolizumab (anti-PD-1 antibodies) have shown significant improvement in recurrence-free survival (RFS) and overall survival (OS) in stage III melanoma. Combination ipilimumab (anti-CTLA-4) plus nivolumab may be used for higher risk, but with increased toxicity.
• Targeted Therapy: For patients with BRAF V600 mutations, the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) is an effective adjuvant option, demonstrating improved RFS and OS in clinical trials.
• Radiotherapy: Adjuvant radiation to the nodal basin may be considered for high-risk features such as extranodal extension or multiple involved nodes, although its role has diminished with effective systemic therapy.

In addition to adjuvant therapy, neoadjuvant approaches are being explored. Clinical trials are evaluating the use of immunotherapy or targeted therapy before surgery to reduce nodal burden and potentially improve outcomes. For patients with in-transit or satellite metastases, intralesional therapies like talimogene laherparepvec (T-VEC) can be used to directly inject a genetically modified virus into tumors, inducing local and systemic immune responses.

Prognosis and Follow-Up

The prognosis for stage III melanoma varies by substage. According to the AJCC 8th edition, the 5-year overall survival for melanoma 3a is approximately 93%, for melanoma 3b about 83%, for melanoma 3c about 69%, and for melanoma 3d (now included in some classifications) lower. However, with modern adjuvant therapies, these rates are improving. Patients with 3a melanoma have an excellent prognosis but still require surveillance. Those with 3b melanoma and 3c melanoma face higher recurrence risks, underscoring the need for close monitoring.

Follow-up for stage III melanoma includes regular dermatologic exams, nodal basin palpation, and imaging at intervals determined by risk. Typically, patients undergo CT or PET-CT scans every 3–6 months for the first 2–3 years, then less frequently. Additionally, blood tests for LDH and S100B may be used. Patients should also be educated on self-examination for new skin lesions or lumps. Lifestyle modifications, including sun protection and avoidance of tanning beds, are essential to prevent new primary melanomas.

In conclusion, stage III melanoma is a complex disease with varying presentations and outcomes. The key to successful management lies in accurate staging, multidisciplinary care, and personalized treatment. With the availability of effective systemic therapies, many patients can achieve long-term remission. Continued clinical trials and research promise even better outcomes for those affected by melanoma 3a, 3b, and 3c. Always consult with a specialized oncology team to determine the best course of action for your specific situation.